Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONGRATS: nivolumab + relatlimab in advanced or metastatic soft-tissue sarcoma
2023-509495-42-00Phase 2Completed
- Sponsor
- Institut Bergonié
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in soft tissue sarcoma (STS) comparing Nivolumab + relatlimab with Nivolumab monotherapy (2 arms). Primary endpoints: 6-month progression-free rate (PFR) per arm and Central radiology review of disease status at 6 months. Started Sep 2024; status: completed.
02
Drugs
nivolumabrelatlimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2023-509495-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509495-42-00.